NEW YORK, Dec. 20-Perlegen, the Affymetrix spin-off, announced two pharmaceutical company deals in pharmacogenomics and disease-related SNP research.
The company said today that it has struck a deal with Pfizer to study the genetics of cardiovascular disease, using its chip-based genotyping technique to identify disease-associated genetic variations.
Further details of the collaboration, including financial information, were not disclosed.
On Dec. 18, Perlegen said it would collaborate with Eli Lilly to identify disease markers using its SNP portfolio and its chip-based whole genome screening technology. In this deal, Perlegen will get research funding, milestone payments, royalties, and an equity investment from Lilly. Perlegen also retains some rights to develop products based on the research.
It has been a busy week for Perlegen: Yesterday, the company said it had struck a similar dealwith Bristol-Myers Squibb.